bcl-2 protein expression in astrocytomas in relation to patient survival and p53 gene status.
作者： E. W. Newcomb , Sandhya K. Bhalla , Clarissa L. Parrish , Roberta L. Hayes , Henry Cohen
关键词: Oncology 、 Gene expression 、 Malignancy 、 Central nervous system 、 Incidence (epidemiology) 、 Gene 、 Internal medicine 、 Tumor suppressor gene 、 Biology 、 Gene mutation 、 Cancer research 、 Central nervous system disease
摘要: bcl-2 protein expression was characterized in a series of 58 astrocytomas from 21 pediatric and 37 adult patients. As part continuing attempt to define relevant prognostic factors which may predict clinical outcome, we have determined the impact accumulation malignant astrocytes on length patient survival. Aberrant overexpression tumor cells detected 57% (12 21) 73% (27 37) cases. Among patients, median survival months showed no relationship with incidence bcl-2-positive tumors. favorable indicator low-tumor grade (P = 0.05). tumors occurred similar frequencies WHO grades III IV malignancy. When tested as variable for survival, 6 patients without among 23 had shorter The same been previously analyzed alterations p53: 4 16 p53 gene mutations. There significant difference related status. between status: approximately equal numbers either wild-type or mutant were negative positive. is high (40–100%) other central nervous system also show low potential. Up-regulation constitutive some types be factor leading more outcome.
springer.com
sci-hub.se 参考文章(34)
Lorenzo Leoncini, Maria Teresa Del Vecchio, Tiziana Megha, Paolo Barbini, Piero Galieni, Stefano Pileri, Elena Sabattini, Filippo Gherlinzoni, Piero Tosi, Rainer Kraft, Hans Cottier, None, Correlations between apoptotic and proliferative indices in malignant non-Hodgkin's lymphomas. American Journal of Pathology. ,vol. 142, pp. 755- 763 ,(1993)
SJ Korsmeyer, Bcl-2 initiates a new category of oncogenes: regulators of cell death. Blood. ,vol. 80, pp. 879- 886 ,(1992) , 10.1182/BLOOD.V80.4.879.BLOODJOURNAL804879
Robyn L. Castleberg, Griffith R. Harsh, John W. Henson, David N. Louis, Lloyd M. Alderson, Human Gliomas with Wild-Type p53 Express bcl-2 Cancer Research. ,vol. 55, pp. 999- 1001 ,(1995)
H Ohgaki, K Watanabe, Y Yonekawa, O Tachibana, P Kleihues, Role of gemistocytes in astrocytoma progression. Laboratory Investigation. ,vol. 76, pp. 277- 284 ,(1997)
Michael J. Winger, David R. Macdonald, J. Gregory Cairncross, Supratentorial anaplastic gliomas in adults. The prognostic importance of extent of resection and prior low-grade glioma. Journal of Neurosurgery. ,vol. 71, pp. 487- 493 ,(1989) , 10.3171/JNS.1989.71.4.0487
James F. Gusella, Andreas von Deimling, Otmar D. Wiestler, David N. Louis, David W. Yandell, Mari Paz Rubio, Accumulation of Wild Type p53 Protein in Human Astrocytomas Cancer Research. ,vol. 53, pp. 3465- 3467 ,(1993)
Motoi Hanada, Masayoshi Harigai, John C. Reed, Toshiyuki Miyashita, Identification of a p53-dependent negative response element in the bcl-2 gene Cancer Research. ,vol. 54, pp. 3131- 3135 ,(1994)
D. M. Hockenbery, M. Zutter, W. Hickey, M. Nahm, S. J. Korsmeyer, BCL2 protein is topographically restricted in tissues characterized by apoptotic cell death. Proceedings of the National Academy of Sciences of the United States of America. ,vol. 88, pp. 6961- 6965 ,(1991) , 10.1073/PNAS.88.16.6961
Bruce S. Chozick, M. Eva Weicker, John C. Pezzullo, Cynthia L. Jackson, Sidney D. Finkelstein, Mary W. Ambler, Mel H. Epstein, Paul W. Finch, Pattern of mutant p53 expression in human astrocytomas suggests the existence of alternate pathways of tumorigenesis Cancer. ,vol. 73, pp. 406- 415 ,(1994) , 10.1002/1097-0142(19940115)73:2<406::AID-CNCR2820730228>3.0.CO;2-S
Claudia Friesen, Ingrid Herr, Peter H. Krammer, Klaus-Michael Debatin, Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nature Medicine. ,vol. 2, pp. 574- 577 ,(1996) , 10.1038/NM0596-574